Company / Cost of Revenue
TG Therapeutics, Inc. Cost of Revenue History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$100.7M
FY2025
5-year range
$265.0K / $100.7M
FY2021-FY2025
Trend
+161.7%
vs FY2024
Sector context
#43 of 85
Health Care
What the data says
At $101M, TG Therapeutics, Inc.'s cost of revenue ranks #43 of 85 in the Health Care sector. Cost of Revenue has increased for 3 consecutive years, from $265,000 in FY2022 to $101M in FY2025.
Based on SEC 10-K filings.
$101M in FY2025 with a 3-year CAGR of +624.3%.
Increased from $14M to $101M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +624.3%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#43 of 85 in Health CareTop 49% of 85This company $100.7M Sector average $2.0B
▼
-94.9% below sector average
Key checks
Key Insights
- TG Therapeutics, Inc.'s cost of revenue has grown for 3 consecutive years.
- 3-year CAGR of +624.3%, indicating consistent growth.
- In FY2025, cost of revenue increased 161.7% year-over-year.
- Ranks #43 out of 85 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $100.7M | +161.7% |
| FY2024 | $38.5M | +172.4% |
| FY2023 | $14.1M | +5232.5% |
| FY2022 | $265.0K | -66.5% |
| FY2021 | $790.0K | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026